DAFTAR PUSTAKA
[ABCSG] Anglian Breast Cancer Study Group. 2000. Prevalence and penetrance of BRCA1and BRCA2 mutations in a population-based series of breast cancer cases.Br J Cancer. 83:1301-8.
Andreoli TE. 2010. Andreoli and Carpenter’s Cecil Essentials of Medicine. 8th
ed. Philadelphia: Elsevier. hlm. 593–628
American Cancer Society. 2015. Breast cancer facts & figures 2015-2016. Atlanta:American Cancer Society Inc.
Anothaisintawee, T., C .Wiratkapun., P. Lerdsitthichai,V. Kasamesup., S. Wongwaisayawan.and J. Srinakarin. 2013.Risk factors of breast cancer: a systematicreview and meta-analysis.Asia Pac J Public Health. 25: 368-87.
Aryandono T., Harijadi, Soeripto. 2006.Hormone Receptor status operable Breast Cancer in Indonesia : Correlation with other prognostic factors and survival, Journal of Cancer Prevantion.7: 21-324
Balman, J., O. Diez., I. Rubio. And M. Castiglione. 2010. BRCA in breast cancer:ESMOclinical practice guidelines. Ann Oncol.21: 20-22.
Bedognetti D, Sertoli RM and Pronzato P. 2011. Concurrent vs Sequential Adjuvant Chemoterapy and Hormone Therapy in Breast Cancer : A Multicentre Randomized Phase III Trial. JNCI.(103)20: 1529-1539.
Brewster, A.M., G.N. Hortobagyi. and K.R. Broglio. 2008. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy.Journal of The National Cancer Institute. 100: 1179-1183.
Brunton, L.L., C. Bruce. and K., Bojorn Knollman. (ed). 2011. Goodman and Gilman’s The Pharmacological Basic of Therapeutics. Twelfth edition.
New York : The McGraw- Hill Companies, Inc. 1382-1388.
Burstein, H.J., A.A Prestrud.and J. Seidenfeld. 2014. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. JClin Oncol.(28)23:3784-96.
Carey, I.A., C.N. Perou. and C.A. Livasy. 2006. Race Breast Cancer Subtype and Survival In the Caroline. BC Study (J) JAMA. 295(21) : 2942-2502.
Cianfrocca. M. and Goldstein. L.J.,Prognostic and Predictive Factors inEarly-Stage Breast Cancer, The oncologist J, 2004.
Clark, GM (2000). Prognostic and Predictive Factors. In: HarrisJR, Lippmann ME, Morrow M, Osborne CK(eds).Diseases ofthe Breast . 2nd ed, Lippincott, Williams &Wilkins,Philadelphia : 489-514.
Coates, A.S., E.P. Winer., A.Goldhirsch., R.D.Gelber., M. Gnant., M.P. Gebhart.
et al. 2015. Improving The Management of Early Breast Cancer: St. Gallen International Expert Consensus On The Primary Therapy of Early Breast Cancer 2015. European Society For Medical Oncology.Ann Oncol.1-38.
Collaborative Group on Hormon Factors in Breast Cancer, 2012. Menarche,menopause, and breast cancer risk: individual participant meta-analysis,including 118964 women with breast cancer from 117 epidemiologicalstudies.Lancet Oncol. 13: 1141–51.
Cui, J., Y.Shen. and R.Li. .2012. Estrogen Synthesis and Signaling Pathways during aging: From Periphery to brain. Elsevier. 19: 197-209
Cuzick, J.,I. Sestak., M. Baum., A. Buzdar., A. Howell., M. Dowsett. and J.F. Forbes. 2010. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of theATAC trial.
LancetOncology.(11)12:1135–1141.
Dahabreh, J. Issa,, L. Helen., S. Fotios., F. George. andM.Samuel. 2008. Transtuzumab in the Adjuvant treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Ramdomized Controlled Trials. The Oncologist.13:620-630.
Dananjaya, R. 2017. Hubungan golongan obat antihormonal dengan ES pada pasien kanker payudara stadium dini di kota Padang tahun 2016. [skripsi]. Pp 1-76
Desai SB, Moonim MT, Gill AK et al ( 2000). Hormone receptor status of breast cancer in India: a study of 798 tumours. The Breast. 9 :267-70.
Devita, V.T., T.S. Lawrence. and S.A. Rosenberg. 2008. Cancer Principle’s & Practice of Oncology. Eight edition. Philadelphia: Lippincott William and Wilkins. 1603-1604.
DiPiro, J.T. and B.G. Wells. 2015. Pharmacotherapy handbook: A
Patophysiologic Approach. Ninth edition.New York: McGraw-Hill Education.
Dellapasqu, S., M. Colleoni., R. Gelber. and A. Goldhirsch. 2005. Adjuvant EndocrineTherapy for Premenopausal Women With Early Breast Cancer, American Society of Clinical Oncology. J Clin Oncol. 23:1736-1750.
Dowsett, M., J.F. Forbes., J. Bradley., A. Ingle and T. Aihara. 2015. Aromatase
inhibitors versus tamoxifen in early breast cancer: patient-level
meta-analysis of the randomised trials.EarlyBreast Cancer Trialists
CollaborativeGroup (EBCTCG).LancetOncology. (386)10001:1341-1352.
[EBCOG] Early Breast Cancer Overview Group.2007. Use of Luteinising
HormoneReleasing Hormone Agonist ad Adjuvant Treatment
inPremenopousal Patients with hormon receptor positive breast cancer: a meta analysis of individual patient from randomised adjuvant trials.
Lancet.369: 1711-1723.
[EBCTCG]Early Breast Cancer Trialists Collaborative Group. 2011. Relevance of breast cancer hormone receptors and other factors to the efficacy of
adjuvanttamoxifen: patient-level meta-analysis of randomised trials. Lancet.
378:771–784.
Edge, S.B., D.R. Byrd. andC.C. Compton.2010. AJCC CancerStaging Manual. 7th ed. New York. Springer. 347-76.
Fang, L., Z. Barekari., B. Zhang., Z. Liu. and X. Zhong. 2011.Targeted Therapy in Breast Cancer: What’s New? European J of Med Sci.
Feitelson, M.A., A. Arzumanyan., R.J. Kulathinal., S.W. Blain., R.F. Holcombe. And J. Mahajna and Marino.,M. 2015. Sustained Proliferation in Cancer: Mechanism and Novel Therapeutic Targets. Journal of Hand Surgery. 35: 25-54.
Freedman, O.C., G.G. Fletcher., S.Gandhi, M.Mates., S.F. Dent., M.E. Trudeau and members of the Early Breast Cancer Systemic Therapy Consensus Panel.2015. Adjuvant endocrine therapy for early breast cancer : a systematic review of the evidence for 2014 Cancer Care Ontario systemic therapy guideline. Current Oncology. (22)1: 95-113.
Fora,A. 2017. Tesis. Analisis Survival Pasien Kanker Payudara Usia Muda Kota Padang Tahun 2011-2016[Tesis]. Padang.Universitas Andalas Padang 132 hal.
Gnant, M. 2011. Zolendronic acid in breast cancer : Latest findings and Interpretation. Med.Oncol.3: 293-301.
Gennari, A., M.P. Sormani. and P. Prozanto .2008. HER2 Status and Efficacy of Adjuvant Anthracyclin in Early Breast Cancer:A pooled Analysis of Randomized Trials. J Natl Cancer Inst.100: 14-20.
GLOBOCAN, WHO. 2018 Estimated cancer incidence, mortalility and prevalenceworldwidein.2012.http://globocan.iarc.fr/pages/fact_sheets_canc er.aspx.[diakses pada 15september 2018].
Goldhirsch A and Winer E.P. A. Goldhirsch, E. P. Winer, A. S. Coates, R. D. Gelber, M. Piccart-Gebhart, B. Thürlimann, H. J. Senn, Kathy S. Albain,
2013. Personalizing The Treatment of Women With EBC; Expert Consensus of The Primary Therapy of EBC. Ann Oncology.
Gray RG, Rea D, and Handley K. 2013. ATTom:Long term effects of continuing adjuvant tamoxifento 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31. 18(5).
Gu, Ran., Weijuan ,jia., Yunjie, zeng., Nanyan, Rao., Yue, Hu. And Shunrong, Li. A comparison of Survival outcomes and Side Effect of TMX Therapy in Premenopousal Estrogen and Progesteron (+) Breast Cancer, 2012.
Guyton, A.C. and J.E. Hall, 2007. Textbook of Medical Physiology 11thEd.
Diterjemahkan oleh Irawati Setiawan dkk; BukuAjar Fisiologi Kedokteran
(Edisi 11). Jakarta: Penerbit Buku Kedokteran EGC.
Hackshaw, Allan., Baum, M.,Fornander, T., Nordenskjold B.,Nicolucci, A.,
Monson, K., Forsyth, S., et al. 2009. Long term efectiveness of adjuvant
Goserelin in Premenopausal women with Early Breast Cancer. J Natl cancer Inst; 101:341-349.
Harvey, .JM., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-81.
Hoffmann, M., Pinho, H.,Cooper, D.J., Sayed, R., Dent, M.D., Gudgeon, A. et al.
2000. BC Incidence and Determinants of Cancer Stage In The Western Cape. Afr Med J.90 (12): 1212-1216.
Irwan, Azamris, Bachtiar H. 2015. Perbandingan Prognosis Subtipe Molekuler Kanker Payudara Antara Pasien Kanker Payudara. Majalah Kedokteran Andalas. 38(3):208-217.
John, E.N., O.A. James., H.D. James., B.K. Michael. and E.T. Joel . 2014.
Abeloffs Clinical Oncology 5th Ed. New York. J Clin Oncol. Inc.
1753-1791
Kabel A.M and Baali F.H,Breast Cancer: Insights into Risk Factors, Pathogenesis, Diagnosis and Management. Journal of Cancer Research and TreatmentVol. 3, No. 2, 2015, pp 28-33.2015
Katz, V.L., G.M. Lentz., R.A. Lobo. and D.M. Gershenson. 2007. Katz:
Comprehensive Gynecology 5th Ed. New York: The Elsevier Inc.
298-324.
Katzung, B., S.B. Masters. and T.A. Trevor. 2014. Farmakologi Dasar Dan Klinik edisi 12.
Kementerian Kesehatan. 2015. Panduan Nasional Penanganan Kanker Payudara. Khambri, D. 2015. Peran Terapi Hormonal pada kanker Payudara. Majalah
Kedokteran Andalas. 38(1): 64-65.
Kobayashi, S., H. Sugiura., Y. Ando., N. Shiraki., T. Yanagi. and H. Yamashita.2012. Reproductive history and breast cancer risk. Breast Cancer. 19: 302-308.
Kumar, V., K.A. Abdul. and C.A. Jon. 2013. Robbins basic Pathology. Phillaedelphia. The Elsevier Inc.19: 681-771.
Lakhani, S.R., Ellis. I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J.WHO
classifications of tumors. Ed 4th. IARC.2012.
Lonning, P., P.Christian., A.Martoni. and C. Zamagni. 2003 Pharmacokinetics
of Third-Generation Aromatase Inhibitor. Seminars in Oncology. (30) 14:
23-32.
Lucille, R.M . 2012. Integrative medicine. New York: Saunders. 692-696.
Lullmann, H., K. Mohr., Mohr K. and Hein L. 2017. Color Atlas of Pharmacology.
Fifth edition. New York: Thieme Stuttgart.444p
Mauri, D., N. Pavlidis., N.P. Polyzos. andJ.P. Ioannidis. 2006. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in
advanced breast cancer: meta-analysis. Journal of the National Cancer
Institute. (98)18:1285–1291.
McGee, E.A. and J.F. Strauss. 2016. Endocrinology: Adult dan Pediatric. New York: Elsevier Inc. 2192-2206.
McGuire, A.,J.A. Brown., C. R. Malone.,M.J.McLaughlin. AndM.J. Kerin. 2015.
Effects of age on the detection and management of breast cancer. 2:
908–29.
McPherson, K.C., M. Steel. and J. M. Dixon. 2000. Breast cancer—epidemiology, risk factors, and genetics. BMJ.321(7261): 624–628.
Megawati, Gambaran ketahanan hidup lima tahun pasien kanker payudaraberdasarkan karakteristik demografi dan faktor klinis di rumah sakit Ciptomangunkusumo tahun 2007-2010. Jakarta, Universitas Indonesia.2011. Pp:35-39.
Moore KL, Dalley AF. 2013. Anatomi Berorientasi Klinis Jilid 1. Edisi ke-5.
Jakarta: Penerbit Erlangga. hlm. 105–12.
Mouridsen, H., M. Gershanovich. and Sun Y. 2003. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.Journalof Clinical Oncology.(21)11:2101–2109.
[NCCN] The Nationale Comprehensive Cancer Network Guideline. 2016. Guideline for Patient Breast Cancer Stage I and II.
Nelson, H.D., B. Zakher., A. Cantor., J. Griffin.and E.S. O’Meara. 2012. Riskfactors for breast cancer for women aged 40 to 49 years: a systematic reviewand meta-analysis. Ann Intern Med.156: 635-48.
Notoatmodjo.2010. Ilmu Perilaku Kesehatan. Jakarta. Rineka Cipta.
Osbone, M.P.andS.K. Bool Bol.2014. Breast Anatomy and Development. InHarris RJ, Lippman ME, Morrow M, Osborne KC, editors. Diseases of the Breast5th Ed. Philladelpia: Wolters Kluwer Health. 3-14.
Osborne, C.K., H. Zhao. and S.A. Fuqua. 2000. Selective Estrogen Receptors Modulators: Structure, Function and Clinical Use. J.Clin Oncol.18: 3172-3186.
Osborne, C.K. and R. Schiff. 2011.Mechanisms of EndocrineResistance in Breast
Cancer.Annual Review of Medicine.62:233-247.
Payne, S.J.L., R.L. Bowen., J.L. Jones. and C.A. Wells. 2008. Predictive
markers in Breast Cancer. Histopathology.(52)1: 82-90.
Polyak, K. Heterogeneity in Breast Cancer. J of Clinical Investigation. 2011; 121(10): 86-3788.
Purwanto, H., H. Djoko, H. Samuel, H.W. Arif Ed., 2014. PERABOI: Panduan Penatalaksanaan Kanker Payudara 2014. 155 hal.
[Pusdatin]Pusat Data dan Informasi Kementrian Kesehatan RI. 2015. Situasi Penyakit kanker. Buletin Jendela Data dan Informasi Kesehatan.
Ramli, M. 2015. Update Breast Cancer management Diagnostic and Treatment. Majalah Kedokteran Andalas.(38)1:1-26.http://jurnalmka.fk.unand.ac.id. [diakses pada 27 februari 2018].
Rianti E, Tirtawati GA, Novita H. Faktor-faktor yang berhubungan dengan kanker payudara wanita. J.Heal Qual, 2012 ; 3 (1): 10-23
Regan, M.M., P. Neven andA.G. Hurder. 2011. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical
trial at 8.1 years median follow-up. Lancet Oncology(12)12:1101–1108.
Romera, J., T.J. Lao. and H. Puertolas. 2011. Update On Adjuvant Hormon Treatment of Early Breast Cancer. Springer Health Care. (28)6:1-18. Rukminingsih, F., A. T. Murti., R. Fita. dan W. Kartika. 2017. Evaluasi Terapi
Adjuvan dan Kejadian Relaps Pada Pasien Premenopousal Early Breast
Cancer di RSUP DR. Sardjito Yogyakarta. Jurnal Manajemen dan Pelayanan Farmasi.6: 25-30.
Sainsbury, R. 2013. The development of endocrine therapy for women with
breastcancer, Princess Anne Hospital, Southampton University
HospitalsFoundation NHS Trust. Southampton, UK. 39:507-517.
Senkus, E., S.Kyriakides., P. Liorca., P.Portmans., A.Thompson., S. Zackrisson et al. 2015. Primary breast cancer: ESMO Clinical Practice Guidelines fordiagnosis, treatment and Follow up. Ann of Oncology.
{SEER] Surveillance, Epidemiology, and End Results. 2014.
http://seer.cancer.gov/. [diakses pada 25 Februari 2018].
Shrigondekar P, Desail S, Bhosale S., Deepti Mankar, Anuya Badwe. 2011. Study of Hormone Receptor Status of Breast Carcinoma and Its Correlation with the Established Prognostic Markers. International Journal of Health Sciences and Research.1(2):109-116.
Sagita Silvia. 2013. Analisis Hubungan Tingkat Pendidikan Pasien dengan Kanker Payudara Stadium Dini di Instalasi Rawat Inap RSCM Jakarta Tahun 2012. [Skripsi]. Fakultas Kesehatan Masyarakat. Universitas Indonesia.
Soerjomataram I., Louwman M.W.J., Ribot J.G., Roukema J.A., Coebergh J.W.W. 2008.An overview of prognostic factors for long-term survivorsof breast cancer. Breast Cancer Res Treat. 107:309–330.
Syahratul Aeni, Ketahanan hidup pasien kanker payudara di RSUP dr. Wahidin Sudiro Husodo, Makassar, 2014.
Shier D, Butler J, Lewis R. 2012. Hole’s Essentials of Anatomy and Physiology. 11th ed. New York: McGraw Hill. hlm. 525–6.
Sjamsuhidajat R, de Jong W. 2013. Buku Ajar Ilmu Bedah. Edisi ke-3. Jakarta: EGC. hlm. 471–496.
Torre A.L, Bray F, Siegel RL, Ferlay J,Lortet J., Jemal A.,Global Cancer Statistics, 2012. CA A Cancer J Clin [Internet]. 2015;65(2):87–108. Availablefrom:http://onlinelibrary.wiley.com/doi/10.3322/caac.21262/full
Untch, M.C. and C. Thomssen.2010. Clinical practice decisions in endocrine therapy.Cancer Investigation. 28 :4–13.
Van D.P, Buerger H., Kuijper A., Van D. Wall E. Breast Carcinogenesis. In: KuererH, editor. Kuerer’s Breast Surgical Oncology. New York: McGraw-Hill; 2010. p. 3–152.
Wei, R., Lau S.S. and Cheung P.S. 2010. Breast carcinoma In Chinese women, does ages affect treatment choice and outcome?. Asian J.Surg.33: 97-102.
Yao, C., Liu Y.,Huang H. and Zhang J. 2010. Correlation between clinicopathological features and postoperative prognosis in patient with breast cancer. Int J Clin Exp Med. 11(3) : 2483-2488.
Yu, Z., Guo, X., jiang, Y., Teng, L., Luo, J. 2017. Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone receptor positive : a systemic review and network meta analysis. Breast cancer.25: 8-16.
Zilli M., A. Grassadonia., N. Tinari., A.D. Giacobbe., S. Gildetti., J. Giampietro. and C. Natoli. 2009. Molecular Mechanism Of Endocrine Resistance and
